254 related articles for article (PubMed ID: 30175971)
21. [Potential mechanism and prognostic value of promoter methylation of PRDM1 gene in diffuse large B cell lymphoma].
Zhang XY; Ma ZP; Cui WL; Chen R; Glinaer A; Miao N; Li XX
Zhonghua Bing Li Xue Za Zhi; 2016 Dec; 45(12):831-837. PubMed ID: 28056297
[No Abstract] [Full Text] [Related]
22. FOXM1-induced upregulation of lncRNA OR3A4 promotes the progression of diffuse large B-cell lymphoma via Wnt/β-catenin signaling pathway.
Meng H; Zhao B; Wang Y
Exp Mol Pathol; 2020 Aug; 115():104451. PubMed ID: 32417392
[TBL] [Abstract][Full Text] [Related]
23. Long non-coding RNA HAGLROS promotes the development of diffuse large B-cell lymphoma via suppressing miR-100.
Shu L; Guo K; Lin ZH; Liu H
J Clin Lab Anal; 2022 Jan; 36(1):e24168. PubMed ID: 34888946
[TBL] [Abstract][Full Text] [Related]
24. High KIF2A expression predicts unfavorable prognosis in diffuse large B cell lymphoma.
Zhang Y; You X; Liu H; Xu M; Dang Q; Yang L; Huang J; Shi W
Ann Hematol; 2017 Sep; 96(9):1485-1491. PubMed ID: 28616658
[TBL] [Abstract][Full Text] [Related]
25. The tumor suppressive role of inhibin βA in diffuse large B-cell lymphoma.
Jiang L; Si T; Yu M; Zeng X; Morse HC; Lu Y; Ouyang G; Zhou JX
Leuk Lymphoma; 2018 May; 59(5):1202-1212. PubMed ID: 28877610
[TBL] [Abstract][Full Text] [Related]
26. Long non‑coding nuclear paraspeckle assembly transcript 1 acts as prognosis biomarker and increases cell growth and invasion in cervical cancer by sequestering microRNA‑101.
Wang L; Zhu H
Mol Med Rep; 2018 Feb; 17(2):2771-2777. PubMed ID: 29207151
[TBL] [Abstract][Full Text] [Related]
27. Coexpression of MYC and BCL-2 predicts prognosis in primary gastrointestinal diffuse large B-cell lymphoma.
Xia B; Zhang L; Guo SQ; Li XW; Qu FL; Zhao HF; Zhang LY; Sun BC; You J; Zhang YZ
World J Gastroenterol; 2015 Feb; 21(8):2433-42. PubMed ID: 25741152
[TBL] [Abstract][Full Text] [Related]
28. Aberrant NEAT1 expression is associated with clinical outcome in high grade glioma patients.
He C; Jiang B; Ma J; Li Q
APMIS; 2016 Mar; 124(3):169-74. PubMed ID: 26582084
[TBL] [Abstract][Full Text] [Related]
29. CXCL9 promotes the progression of diffuse large B-cell lymphoma through up-regulating β-catenin.
Ruiduo C; Ying D; Qiwei W
Biomed Pharmacother; 2018 Nov; 107():689-695. PubMed ID: 30130730
[TBL] [Abstract][Full Text] [Related]
30. [Expression of dendritic cell marker CD21 is a positive prognostic factor in diffuse large B-cell lymphoma].
Yao WK; Wang YP; Peng F; Zheng Y; Zou YB; Gao JN; Liu XL
Zhonghua Bing Li Xue Za Zhi; 2012 Dec; 41(12):818-22. PubMed ID: 23324230
[TBL] [Abstract][Full Text] [Related]
31. Downregulation of long non-coding RNA TUG1 suppresses tumor growth by promoting ubiquitination of MET in diffuse large B-cell lymphoma.
Cheng H; Yan Z; Wang X; Cao J; Chen W; Qi K; Zhou D; Xia J; Qi N; Li Z; Xu K
Mol Cell Biochem; 2019 Nov; 461(1-2):47-56. PubMed ID: 31338678
[TBL] [Abstract][Full Text] [Related]
32. HDAC6 regulates microRNA-27b that suppresses proliferation, promotes apoptosis and target MET in diffuse large B-cell lymphoma.
Jia YJ; Liu ZB; Wang WG; Sun CB; Wei P; Yang YL; You MJ; Yu BH; Li XQ; Zhou XY
Leukemia; 2018 Mar; 32(3):703-711. PubMed ID: 29135973
[TBL] [Abstract][Full Text] [Related]
33. MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma.
Go H; Jang JY; Kim PJ; Kim YG; Nam SJ; Paik JH; Kim TM; Heo DS; Kim CW; Jeon YK
Oncotarget; 2015 Jun; 6(17):15035-49. PubMed ID: 25909227
[TBL] [Abstract][Full Text] [Related]
34. Expression and clinical significance of ubiquitin‑specific‑processing protease 34 in diffuse large B‑cell lymphoma.
Li C; Huang L; Lu H; Wang W; Chen G; Gu Y; Zhou Q; Peng Z; Feng Z
Mol Med Rep; 2018 Nov; 18(5):4543-4554. PubMed ID: 30221700
[TBL] [Abstract][Full Text] [Related]
35. Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study.
Hu LY; Xu XL; Rao HL; Chen J; Lai RC; Huang HQ; Jiang WQ; Lin TY; Xia ZJ; Cai QQ
Chin J Cancer; 2017 Dec; 36(1):94. PubMed ID: 29246182
[TBL] [Abstract][Full Text] [Related]
36. Differential expression of miRNAs as biomarkers for predicting the outcomes of diffuse large B-cell lymphoma patients.
Hu M; Wang X; Liu N; Ding K; Zhang G; Liu X
Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 34109978
[TBL] [Abstract][Full Text] [Related]
37. Predictive analysis of long non-coding RNA expression profiles in diffuse large B-cell lymphoma.
Zhu D; Fang C; Li X; Geng Y; Li R; Wu C; Jiang J; Wu C
Oncotarget; 2017 Apr; 8(14):23228-23236. PubMed ID: 28423571
[TBL] [Abstract][Full Text] [Related]
38. FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas.
Brown PJ; Wong KK; Felce SL; Lyne L; Spearman H; Soilleux EJ; Pedersen LM; Møller MB; Green TM; Gascoyne DM; Banham AH
Leukemia; 2016 Mar; 30(3):605-16. PubMed ID: 26500140
[TBL] [Abstract][Full Text] [Related]
39. The long non-coding RNA NONHSAG026900 predicts prognosis as a favorable biomarker in patients with diffuse large B-cell lymphoma.
Zhao S; Fang S; Liu Y; Li X; Liao S; Chen J; Liu J; Zhao L; Li H; Zhou W; Shen W; Dong X; Xiang R; Wang L; Zhao Y
Oncotarget; 2017 May; 8(21):34374-34386. PubMed ID: 28423735
[TBL] [Abstract][Full Text] [Related]
40. Long noncoding RNA NEAT1 is an unfavorable prognostic factor and regulates migration and invasion in gastric cancer.
Fu JW; Kong Y; Sun X
J Cancer Res Clin Oncol; 2016 Jul; 142(7):1571-9. PubMed ID: 27095450
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
